Psychedelic Companies Hope At-Home DNA Tests Bring Better Highs

Twitter icon

Spit into a tube and pop it in the mail, and the lab results may lead to a better high—or at least a safer one. That’s the premise of a home saliva testing kit sold for $199 by Endocanna Health Inc., which looks for 57 genetic traits that could influence a customer’s response to marijuana, so they can select the best strain and correct dose. The company also plans to look at similar factors for a range of psychotropic drugs.

“Your DNA is your blueprint,” says Len May, chief executive officer of the Burbank, Calif.-based startup. “It gives you a GPS that can guide you to an experience that is more optimal and helps you avoid sharp corners.”

Endocanna is among a handful of early-stage companies following in the footsteps of precision medicine by trying to help people understand how they’ll react to cannabis or psychedelic drugs, such as psilocybin, MDMA, DMT, and ketamine. Companies researching alternative therapies for depression, addiction, chronic pain, and other afflictions want part of the $27 billion global market for traditional psychiatric drugs. They’re trying to solve the piece of the puzzle that holds many people back from microdosing magic mushrooms or undergoing marijuana therapy: fear of a bad trip—or even lasting psychosis.

Pharmacogenomics, the branch of pharmacology concerned with how genetic factors influence reactions to drugs, has already seen some success in oncology. Although there’s no scientific consensus about whether a person’s response to any kind of psychiatric drug can be predicted with genetics, companies including Endocanna are already wading into research and even direct-to-consumer kits. If they can succeed in preventing extreme reactions to psychedelic drugs, it could smooth a path for the industry more broadly.

The risks are more significant than just bad trips. Marijuana is often recommended to ease anxiety, but it can also provoke it in some people. The National Institute on Drug Abuse says smoking high-potency marijuana could increase the chances of developing psychosis. On the flip side, a 2015 analysis of U.S. patient data found that 19,299 Americans who took classic psychedelics such as LSD, psilocybin, and mescaline weren’t at increased risk for developing problems such as schizophrenia, psychosis, depression, or anxiety, or of committing suicide.

The risks aren’t deterring investors. The Canadian Securities Exchange said $277 million has been raised for psychedelics companies since 2020, and $11.25 billion has been raised for cannabis and hemp companies since 2016. Vancouver-based Entheon Biomedical Corp., which sells a mail-order saliva test for people considering psychedelics, priced at $89, is among them. The early-stage company went public last year through a reverse takeover.

Entheon’s psychedelic test looks at five factors: a liver enzyme for ketamine metabolism, serotonin receptor variations to gauge “psychedelics sensitivity,” and three other factors to weigh “mental health risk” by analyzing genes believed to influence responses to THC and CBD—including a test for the AKT1 gene, which the National Institute on Drug Abuse has identified as potentially linked to a higher risk of psychosis in people who use marijuana.

The company grew out of CEO Timothy Ko’s desire to help his opiate-addicted brother, who tried traditional treatments for a variety of mental ailments before dying two years ago. “Some of the difficulty that we faced as a family was that there was a lot of uncertainty as to what he was actual suffering from and what medications might be given to him,” Ko says.

Griffiths says it’s too early to know if a psychedelic treatment plan can be personalized to account for someone’s genes. “Right now within precision psychiatry, there aren’t even good genomic predictors of responses to most interventions,” he says. “I’m not aware that there are any within psychedelics, either.”

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 
Article category: 
Regional Marijuana News: